Stay updated with breaking news from Sareum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor. ....
Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year’s £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations. ....
Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares. ....
Sareum (LON:SAR – Get Rating)‘s stock had its “buy” rating restated by analysts at Peel Hunt in a report issued on Tuesday, MarketBeat.com reports. They presently have a GBX 304 ($3.78) price target on the stock. Peel Hunt’s target price suggests a potential upside of 133.85% from the stock’s previous close. Sareum Price Performance Shares […] ....
Sareum continues to make rapid progress with its clinical plans for SDC-1801 (lead TYK2/JAK1 kinase inhibitor) and has announced the dosing of first participants (Phase Ia study) just a month into receiving ....